XBiotech (XBIT) Competitors $3.18 -0.04 (-1.24%) Closing price 03:58 PM EasternExtended Trading$3.20 +0.01 (+0.47%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIT vs. ATXS, NBTX, FULC, IVA, TNXP, AURA, ARCT, CRVS, ABEO, and OLMAShould you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Inventiva (IVA), Tonix Pharmaceuticals (TNXP), Aura Biosciences (AURA), Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), Abeona Therapeutics (ABEO), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. XBiotech vs. Its Competitors Astria Therapeutics Nanobiotix Fulcrum Therapeutics Inventiva Tonix Pharmaceuticals Aura Biosciences Arcturus Therapeutics Corvus Pharmaceuticals Abeona Therapeutics Olema Pharmaceuticals Astria Therapeutics (NASDAQ:ATXS) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability. Which has more volatility & risk, ATXS or XBIT? Astria Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Do analysts rate ATXS or XBIT? Astria Therapeutics presently has a consensus target price of $29.00, suggesting a potential upside of 357.27%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Astria Therapeutics is more favorable than XBiotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14XBiotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ATXS or XBIT more profitable? XBiotech's return on equity of -15.60% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -56.39% -36.08% XBiotech N/A -15.60%-14.64% Which has better valuation and earnings, ATXS or XBIT? XBiotech has higher revenue and earnings than Astria Therapeutics. XBiotech is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$94.26M-$2.01-3.16XBiotech$4.01M24.18-$38.53M-$0.92-3.46 Does the media refer more to ATXS or XBIT? In the previous week, Astria Therapeutics had 25 more articles in the media than XBiotech. MarketBeat recorded 26 mentions for Astria Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.17 beat Astria Therapeutics' score of 0.94 indicating that XBiotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astria Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XBiotech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in ATXS or XBIT? 99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 4.5% of Astria Therapeutics shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryXBiotech beats Astria Therapeutics on 8 of the 15 factors compared between the two stocks. Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIT vs. The Competition Export to ExcelMetricXBiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.96M$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-3.4620.3730.4325.14Price / Sales24.18238.33392.4187.63Price / CashN/A42.3737.0358.50Price / Book0.567.918.956.21Net Income-$38.53M-$54.72M$3.26B$265.38M7 Day Performance-1.85%1.58%1.03%-1.12%1 Month Performance7.80%5.81%4.28%-0.68%1 Year Performance-51.60%8.71%28.38%18.92% XBiotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBITXBiotech1.7302 of 5 stars$3.18-1.2%N/A-48.2%$96.96M$4.01M-3.46100News CoverageATXSAstria Therapeutics2.8715 of 5 stars$6.68+6.4%$29.00+334.1%-46.8%$354.41MN/A-3.5730NBTXNanobiotix0.6295 of 5 stars$7.18-2.8%$8.00+11.5%+78.8%$353.82M$39.18M0.00100News CoverageGap UpFULCFulcrum Therapeutics1.5916 of 5 stars$6.34-2.3%$7.57+19.4%-30.3%$351.05M$80M-5.20100IVAInventiva3.3639 of 5 stars$3.52-1.7%$10.40+195.5%+89.3%$342.47M$9.95M0.00100Positive NewsTNXPTonix Pharmaceuticals2.6867 of 5 stars$44.97-3.3%$70.00+55.7%-5.1%$342.04M$10.09M-0.0250AURAAura Biosciences1.8756 of 5 stars$6.84+0.6%$22.00+221.6%-16.2%$341.83MN/A-3.6050Analyst UpgradeAnalyst RevisionARCTArcturus Therapeutics2.9595 of 5 stars$11.39-4.4%$50.80+346.0%-18.4%$323.01M$152.31M-4.50180High Trading VolumeCRVSCorvus Pharmaceuticals2.8992 of 5 stars$4.37+1.4%$15.00+243.2%+23.6%$321.15MN/A-4.3330ABEOAbeona Therapeutics4.4056 of 5 stars$6.28+0.3%$19.25+206.5%+36.5%$320.24M$3.50M-4.9490Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals1.8241 of 5 stars$4.57-1.5%$24.50+436.1%-55.6%$317.48MN/A-2.2770News Coverage Related Companies and Tools Related Companies ATXS Competitors NBTX Competitors FULC Competitors IVA Competitors TNXP Competitors AURA Competitors ARCT Competitors CRVS Competitors ABEO Competitors OLMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIT) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access